Genetic Polymorphisms Associated with Insulin Resistance Risk in Normal BMI Indians - Thummala, Sabitha; Khan Ghori, Junaid Ahmed; Saikia, Katherine; Fathima, Sarah; Kruthi, Nithya; Balamurali, AR; Ranganathan, Rahul (medRxiv, 2024)
Background Insulin resistance (IR) contributes significantly to the onset of metabolic disorders, such as type 2 diabetes mellitus and cardiovascular diseases. Identifying genetic markers associated with IR can offer insights into its mechanisms and potential therapeutic targets.Objective This study investigated the association between four single nucleotide polymorphisms (SNPs) and insulin resistance among 191 individuals in the Indian population.Methods A literature review identified four SNPs linked to IR. Participants were divided into groups based on insulin resistance and sensitivity, determined by the Homeostasis Model Assessment for Insulin Resistance (HOMA2-IR). DNA was extracted for genotyping using Illumina Infinium Global Screening Array (GSA) V3. Case-control analysis assessed SNP-genotype associations with insulin resistance and other clinical parameters.Results Among 191 participants, 57 were insulin-resistant and 134 were insulin-sensitive. Significant associations (P < 0.05) were found between selected SNPs and IR. SNP rs920590 showed the strongest association, with the T allele associated with increased IR risk (odds ratio = 4.01, 95% CI 1.55-10.34; p < 0.0014). Additionally, serum LDL cholesterol, serum triglycerides, HbA1c, Insulin fasting and fat mass show significant differences in cases and controls.Conclusion This study validates genetic markers linked to insulin resistance (IR) in the Indian population and elucidates their roles in IR pathogenesis. Understanding these markers can inform personalised therapeutic strategies for metabolic disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Answer Genomics Pvt Limited.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol received approval from the Answer Genomics Ethical Review Committee. REF.NO.:10/NRT/23-24 AERC Number:10001/AERC/24 I am pleased to inform you that the aforementioned study has been approved by the Answergenomics Ethical Review Committee (AERC) in accordance with the compliance of the Section 4, National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, ICMR (2017). All research activities must be conducted in accordance with the approved submission. It is your responsibility to fulfil the following requirements of approval: 1. Changes, amendments and addenda to the protocol, informed consent, or other study materials must be submitted to AERC for re-review and approval prior to implementation. 2. Any unanticipated problems, adverse events, protocol violations, social harm, or any new information becoming available which could change the risk/benefit ratio must be reported to the AERC. The AERC concluded that the Principal Investigator has taken sufficient safeguards to carry out the study. Therefore, the AERC approves the proposal for conducting the survey submitted in the protocol. This approval is based on your submission of study protocol (refer email sabitha@nugenomics.in dated 29/12/2024) Any deviation from this protocol will require further approval of the AERC. This is valid for one year from the date of approval, mentioned geographical location and presented sample. After the completion of the study, please submit the study report to the AERC.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.nugenomics.in/ (IR)Insulin resistance(SNPs)single nucleotide polymorphisms(HOMA2-IR)Homeostasis Model Assessment for Insulin Resistance(GSA)Global Screening Array(DM)Diabetes Mellitus(NCDs)noncommunicable diseases(BMI)Body mass index(BF%)body fat percentage(TG)triglycerides(LDL-C)high-density lipoprotein cholesterol(LDL-C)low-density lipoprotein cholesterol(TC)total cholesterol(FPG)and fasting plasma glucose(ORs)odds ratios(CIs)confidence intervals(LD)linkage disequilibrium(HWE)Hardy-Weinberg equilibrium(AIC)Akaike Information Criterion(BIC)Bayesian Information Criterion(T2D)type 2 diabetes